Saxenda vs. Ozempic/Wegovy Cost: Which GLP-1 Drug Is Worth It for Weight Loss?
In 2021, Wegovy launched and almost immediately made Saxenda look obsolete. Both are GLP-1 receptor agonists. Both are injected. Both reduce appetite and help you lose weight. But the clinical trial data told a stark story: semaglutide produced roughly twice the weight loss of liraglutide at similar monthly costs. So why does Saxenda still have 2 million+ active prescriptions in the US? The answer is messier than the trials suggest.
What These Drugs Are
Liraglutide (Saxenda) — Novo Nordisk’s daily injectable GLP-1 agonist, FDA-approved for chronic weight management in 2014. It’s a different formulation of the same molecule as Victoza (the diabetes version) at a higher dose.
Semaglutide (Ozempic / Wegovy) — Also Novo Nordisk. Ozempic is once-weekly semaglutide approved for type 2 diabetes; Wegovy is once-weekly semaglutide FDA-approved specifically for weight loss at a higher dose. Same molecule, different approval pathways.
Both work by mimicking GLP-1, a gut hormone that slows gastric emptying, stimulates insulin release, and most importantly, tells your brain you’re full.
Cost Comparison
| Drug | Formulation | Monthly Cash Price | With Manufacturer Savings Card | With Insurance (est. co-pay) |
|---|---|---|---|---|
| Saxenda (liraglutide) | Daily injection, 6mg/mL pen | $1,200–$1,500 | $25–$99 (Novo Nordisk offer, income limits apply) | $25–$150 |
| Ozempic (semaglutide 0.5–2mg) | Weekly injection, 2mg/3mL | $900–$1,100 | $25 (Novo Nordisk offer, income limits apply) | $25–$100 |
| Wegovy (semaglutide 2.4mg) | Weekly injection, 2.4mg/0.75mL | $1,300–$1,400 | $25 (new patients, income limits) | $25–$200 |
| Compounded semaglutide* | Weekly injection | $200–$500 | N/A | Not covered |
*Compounded semaglutide was widely available 2022–2025 from telehealth pharmacies. FDA declared semaglutide off the shortage list in 2025; compounding is now more restricted. Verify legality and safety with your prescribing physician.
At full cash price, Saxenda is actually slightly more expensive than Wegovy — and delivers meaningfully less weight loss. That price-to-efficacy gap is the main argument against starting with liraglutide for most new patients.
Efficacy: What the Trial Data Shows
The SCALE Obesity and Prediabetes trial (published in NEJM, 2015) established the liraglutide benchmark: patients lost 5.4 kg (about 12 lbs) more than placebo over 56 weeks, representing roughly 5–7% of baseline body weight.
The STEP 1 trial (also NEJM, 2021) tested semaglutide 2.4 mg weekly and found mean weight loss of 14.9% of body weight — more than double the liraglutide result. Participants without type 2 diabetes averaged losing about 34 lbs.
| Metric | Saxenda (Liraglutide) | Wegovy (Semaglutide) |
|---|---|---|
| Average weight loss vs. placebo | ~5–7% body weight | ~12–15% body weight |
| Injection frequency | Daily | Once weekly |
| FDA approval year (weight loss) | 2014 | 2021 |
| Half-life | ~13 hours (hence daily dosing) | ~7 days (hence weekly dosing) |
| Typical side effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea (often milder) |
| Titration period | 5 weeks to full dose | 16–20 weeks to full dose |
The daily vs. weekly injection difference is significant for patient adherence. Forgetting a weekly shot once in a while has a much smaller pharmacological impact than inconsistency with a daily drug.
When Saxenda Might Still Make Sense
There are a few scenarios where liraglutide is legitimately the better choice:
- Insurance covers Saxenda but not Wegovy. Some formularies have Saxenda listed but haven’t added Wegovy yet. If your co-pay is $25 vs. $1,300/month cash, that formulary difference overrides the efficacy argument.
- Sensitivity to semaglutide side effects. A small subset of patients tolerate liraglutide GI side effects better than semaglutide’s — possibly related to different titration curves.
- Prior authorization pathway. Some insurers require liraglutide trial before approving Wegovy as a step-therapy requirement.
Side Effects: How They Differ
Both drugs share the GLP-1 side effect profile: nausea, vomiting, constipation, diarrhea — particularly during dose escalation. There are nuances:
Saxenda’s side effects tend to hit faster (within the first 1–2 weeks) and can feel acute since the drug peaks and drops daily. Some patients describe it as “waves” of nausea.
Wegovy’s GI side effects are spread across a slower titration (16–20 weeks to reach 2.4 mg) and many patients find the severity more manageable. That said, the longer half-life means when nausea does appear, it can linger for days rather than hours.
Both drugs carry a black box warning for thyroid C-cell tumors based on rodent studies. Neither is recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Insurance Coverage Differences
Wegovy (semaglutide for weight loss) has had choppy insurance coverage since its 2021 launch. Many commercial insurers added it quickly; Medicare Part D was explicitly prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act (TROA) was under consideration. As of 2024, Medicare covers Wegovy for patients with established cardiovascular disease, following the SELECT trial data showing a 20% reduction in major cardiovascular events.
Ozempic (the diabetes formulation) is frequently covered for diabetic patients and sometimes prescribed off-label for weight loss — though this is increasingly flagged by payers.
Saxenda has been on more formularies longer and may have better coverage in some older employer plans that haven’t updated to include Wegovy.
Which One Should You Choose?
The honest answer: most new patients should ask about semaglutide first. The weight loss difference is substantial — nearly double on average — and the weekly injection schedule improves adherence.
Saxenda makes most sense if:
- Your formulary covers it at a low co-pay and Wegovy isn’t covered
- You’ve tried semaglutide and had intolerable side effects
- Your prescriber has clinical reasons for preferring it
If neither is covered by insurance and you’re paying full cash price, neither is cheap — both are $1,000+/month. At that price point, it’s worth asking your bariatric physician about tirzepatide vs. semaglutide cost, since Zepbound (tirzepatide) now offers strong efficacy at competitive cash pricing. And if medication costs are consistently in the four figures per month, the long-term economics of bariatric surgery financing options may be worth comparing.
For current per-medication pricing, see our dedicated Saxenda cost guide and Wegovy cost guide.
Disclaimer: BariatricCostGuide provides cost data for educational purposes only. We are not a medical provider, insurance company, or financial advisor. All costs are estimates based on published data and vary by location, facility, surgeon, insurance plan, and individual health factors. Consult a board-certified bariatric surgeon and your insurance carrier for personalized medical and cost advice.